VF
CNTX icon

Virtu Financial’s Context Therapeutics CNTX Stock Holding History

Virtu Financial’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,100
Closed -$61K – 1697
2026
Q1 		$61K Sell
23,100
-5,821
-20% -$13.6K ﹤0.01% 1256
2025
Q4 		$43K Buy
+28,921
New +$33.8K ﹤0.01% 1323
2025
Q1 		– Sell
-11,638
Closed -$12K – 1454
2024
Q4 		$12K Buy
+11,638
New +$20.1K ﹤0.01% 1366
2023
Q2 		– Sell
-41,191
Closed -$23K – 1591
2023
Q1 		$23K Sell
41,191
-16,264
-28% -$12.3K ﹤0.01% 1220
2022
Q4 		$38K Buy
+57,455
New +$61.9K 0.01% 1129
2022
Q3 		– Sell
-46,445
Closed -$98K – 1791
2022
Q2 		$98K Buy
+46,445
New +$87K 0.01% 957
2022
Q1 		– Sell
-53,521
Closed -$142K – 1571
2021
Q4 		$142K Buy
+53,521
New +$267K 0.01% 970

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Virtu Financial's CNTX Position: Q2 2026 in Review

Virtu Financial sold out of Context Therapeutics (CNTX) in Q2 2026, closing a stake of 23,100 shares — an estimated $61K sold.

Virtu Financial first reported a position in CNTX in Q4 2021 and held it in 7 quarters. The position peaked at $142K in Q4 2021. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Virtu Financial reported no remaining Context Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 23,100 Context Therapeutics shares in Q2 2026, an estimated $61K.
  • Virtu Financial first reported a position in Context Therapeutics in Q4 2021 and held it in 7 quarters.
  • Virtu Financial's Context Therapeutics position peaked at $142K in Q4 2021.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.